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Objectives After completing this article, readers should be able to:
1. Review the discoveries and advances in teratology, genetics, toxicology, and clinical
teratology counseling in the past 50 years.
2. Explain the changes that have occurred in some basic principles of teratology.
3. List the drugs, chemicals, infections, and other environmental agents that may harm
the developing embryo.
4. Explain how congenital malformations can be prevented and how to manage
pregnancies in which the embryo has a congenital malformation.
5. Delineate the principles involved in evaluating the risks and effects of environmental
toxicants and know how to evaluate the potential risks of a specific exposure.
6. Discuss how to evaluate whether a child’s congenital malformation is caused by an
environmental exposure or other mechanism.
Introduction
During the first half of the 20th century, the field of teratology (the study of birth defects)
was represented sparsely in the medical literature. Pediatricians who graduated from
medical school in the 1950s were taught that the correct number of human chromosomes
was 48, until the number was reported accurately as 46 by Tijo and Levan in 1956. (1)
Gregg had described the teratogenicity of rubella virus infection during pregnancy in
1941. (2) The teratogenic risk of the folic acid antagonists (aminopterin) was established
in humans, (3)(4) and experimental studies indicated that nutritional deficiencies could
produce congenital malformations (CMs) in animals. (5)(6)(7)
In the 1950s, teratologists were aware that only a small percentage of birth defects were
caused by drugs, chemicals, and physical agents. (5) By 2007, further information
confirmed the viewpoint that birth defects caused by drugs, chemicals, and physical agents
account for a small but significant percentage of total birth defects (Table 1). (6)(7)(8)(9)
However, avoiding teratogenic drugs and chemicals or reducing teratogenic maternal
disease states has a major impact on an individual pregnancy and family.
Reproductive problems encompass a multiplicity of diseases, including sterility, infer-
tility, spontaneous abortion (miscarriage), stillbirth, congenital malformations (due to
environmental or hereditary causes), fetal growth restriction, and prematurity. (6)(7)
(8)(9) Because these clinical problems occur commonly in the general population,
environmental causes are not always easy to corroborate (Table 2). Severe CMs occur in 3%
of births.
According to the Centers for Disease Control and Prevention (CDC), severe CMs
include those birth defects that cause death, hospitalization, or intellectual disability;
necessitate significant or repeated surgical procedures; are disfiguring; or interfere with
physical performance. Each year in the United States, 120,000 infants are born with
severe birth defects. Genetic diseases occur in approximately 11% of births. Spontaneous
mutations account for less than 2% to 3% of genetic diseases (Table 1). Therefore,
mutations induced from preconception exposures to environmental mutagens are
difficult endpoints to document (Table 2). Birth defects account for 440,000 deaths
among children each year in developing nations, representing 3.7% of the deaths in
children. In the United States, 25% of infant deaths are due to lethal CMs.
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Pediatricians and pediatric subspecialists cannot ig-
nore the medical problems associated with CMs because
they are the leading cause of death in infancy (1 to 12
months of age). (6)(7) They are the fifth leading cause of
death from disease in the entire population and are
responsible for a large number of hospitalizations. Al-
though clinicians who care for pregnant women play a
very important role in the effort to prevent CMs, pedia-
tricians also can contribute to the preventive effort and
counseling of families in their practices who have a child
born with a CM.
Advances in Teratology and Genetics During
the Last Half of the 20th Century
During the past 50 years, substantial discoveries and
advances have been made in teratology, genetics, toxi-
cology, and clinical teratology counseling (Table 3). The
number of genetic diseases catalogued in the post-World
War II period was approximately 1,500. (10)(11) In the
year 2006, the Human Genome Project identified more
than 6,000 single-gene genetic abnormalities, many of
which manifest as CMs. (12) Also, a large number of
chromosome abnormalities and complex or polygenic
genetic diseases involve multiple genetic loci (eg, diabe-
tes and obesity).
The field of prenatal diagnosis,
using ultrasonography, karyotyp-
ing, biochemical studies, and mo-
lecular biology studies, has ex-
panded the ability to diagnose
anatomic malformations, metabolic
diseases, and genetic diseases in the
embryo and to determine the cause
of many birth defects that previ-
ously were listed in the unknown
category (Tables 1 and 2). The abil-
ity to determine the cause of a
child’s birth defect has improved, as
well as the ability to inform the
family about the risk of recurrence.
(11)(13)(14)(15)(16)(17)(18)
The topic of interruption of
pregnancy is controversial in many
countries and continues to be de-
bated both politically and ethically,
but it offers the opportunity to
eliminate nonviable or severelymal-
formed embryos early in preg-
nancy. Physicians should under-
stand that the family makes the
decision on how to manage preg-
nancies affected with serious abnormalities; the physi-
cian’s role is as an educator who defines the problem and
prognosis. Nature frequently preempts politics and eth-
ics, with most early spontaneous abortions occurring in
embryos that have either karyotype abnormalities or
serious anatomic malformations. Another reason that
interruption of pregnancy is controversial is because the
procedure does not prevent CMs; rather, it eliminates
severely malformed embryos very early in pregnancy.
Abnormal pregnancies can be diagnosed early in gesta-
tion through maternal serum biochemical markers, and
ultrasonography, amniocentesis, and chorionic villous
sampling can aid in the diagnosis of very serious or fatal
abnormalities early in pregnancy.
Discovery of new teratogens, such as the angiotensin-
converting enzyme inhibitors and misoprostol, have
taught clinicians to be prepared to accept new principles
in teratology that are discovered when new teratogens
are identified that do not follow the “old” rules, such as
the belief that severe anatomic CMs can be induced only
during early organogenesis. (19)(20)(21)(22)(23)(24)
(25)(26)(27)(28)(29)(30) Microcephaly, intellectual
disability, growth restriction, and vascular disruptive
phenomena can be induced by embryotoxic exposures in
the second and third trimesters (Table 4).
Table 1. Reproductive and Developmental Effects
Condition Frequency
Immunologically and clinically diagnosed spontaneous
abortions per million conceptions (20% have lethal
malformations or chromosome abnormalities that
cause spontaneous abortion before the first month
of gestation [first missed menstrual period])
350,000
Clinically recognized spontaneous abortions per
million clinically recognized pregnancies
150,000
Spontaneous abortion after the first missed menstrual
period
Genetic diseases per million births 110,000
Multifactorial or polygenic genetic environmental
interactions
90,000
Dominantly inherited disease 10,000
Autosomal recessive and sex-linked genetic disease 1,200
Cytogenetic (chromosomal abnormalities) 5,000
New mutations in the developing ova or sperm
before conception
3,000
Major malformations (genetic, unknown, environmental) 30,000
Prematurity (Ireland, 55,000; United States, 124,000) 69,000
Fetal growth restriction 30,000
Stillbirths (>20 wk) 4,000 to 20,900
Infertility 7% of couples
Modified from Brent. (7)
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Environmental Causes of Developmental and
Reproductive Effects
Obstetricians and perinatologists obviously must be fa-
miliar with drugs, chemicals, infections, and other envi-
ronmental agents (Table 4) that may harm the develop-
ing embryos of their pregnant patients, but this an area of
importance to pediatricians as well. A comprehensive
textbook chapter on the environmental causes of birth
defects may be helpful to pediatricians who wish to have
more extensive information about teratogenic agents.
(14) Pediatricians may encounter several specific situa-
tions related to birth defects:
● Because teenagers under the care of a pediatrician
do get pregnant, it is important to consider the
possibility of pregnancy when prescribing medica-
tions for teenage patients. In particular, the admin-
istration of retinoids (isotretinoin), anticonvul-
sants, and vaccines may place the pediatrician at
legal risk. (31)
● Some of pediatric patients have CMs or other de-
velopmental effects and the parents may ask the
pediatrician about the cause of their child’s medical
problems. The pediatrician should be prepared to
answer the questions or refer the family to a clinical
teratologist or geneticist.
● The pediatrician may attend a
delivery of a malformed child
and subsequently be involved
in litigation as a fact witness or
defendant.
● Mothers of pediatric patients
may become pregnant and
ask their child’s pediatrician
about the risk of medications,
immunizations, or other envi-
ronmental exposures that may
be prescribed during preg-
nancy.
● Pediatricians should encour-
age teenagers to receive the
human papillomavirus vaccine
and encourage all women of
reproductive age to take 400
g of folic acid and 6 g of
vitamin B-12 each day to re-
duce the risk of neural tube
defects. (15)
Pediatricians have a multitude of
educational aids to assist in their
evaluations, including consulta-
tions with clinical teratologists
and geneticists, the medical literature, OMIM (the
web site for the Online Mendelian Inheritance of Man
supported by the National Institutes of Health) (11)
and TERIS (the web site of the Teratogen Information
Services located at the University of Washington),
(17) and publications that review the field of CMs.
(12)(13)(14)(16)(18)(19)(20)(21)(22)(23)(24)(25)
(26)(27)(28)(29)(30)
Prevention of Congenital Malformations and
Management of Affected Pregnancies
Some of the discoveries pertaining to the causes of in
utero developmental problems have been translated into
preventive measures (Table 5) The implementation of all
of these measures could reduce the prevalence of birth
defects and other developmental problems. The Centers
for Disease Control and Prevention (CDC) has initiated
a campaign to emphasize that some birth defects can
be prevented. (32) A fact sheet from this campaign is
published in the online version of this article (see data
supplement). The National Academy of Sciences has
published a report addressing the problem of reducing
birth defects in developing nations. (33) Individual tera-
tologists have been attempting to accomplish this goal
for years with regard to the prevention of neural tube
Table 2. Causes of Congenital Malformations
Observed During the First Year After Birth
Suspected Cause
Percent of
Total
Unknown 65
Polygenic
Multifactorial (gene-environment interactions)
Spontaneous errors of development
Synergistic interactions of teratogens?
Genetic 15 to 25
Autosomal and sex-linked inherited genetic disease
Cytogenetic (chromosomal abnormalities)
New mutations
Environmental 10
Maternal conditions: alcoholism, diabetes, endocrinopathies,
phenylketonuria, smoking and nicotine, starvation,
nutritional deficits
4
Infectious agents: rubella, toxoplasmosis, syphilis, herpes simplex,
cytomegalovirus, varicella-zoster, Venezuelan equine encephalitis,
parvovirus B19
3
Mechanical problems (deformations): amniotic band constrictions,
umbilical cord constraint, disparity in uterine size and uterine
contents
1 to 2
Chemicals, prescription drugs, high-dose ionizing radiation,
hyperthermia
2 to 3
Modified from Brent. (7)
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defects (NTDs) through folic acid supplementation.
(15)(34)(35)(36)(37)(38)(39)(40)
Folic Acid
Folic acid supplementation of grain was recommended
following the 1991 publication of the controlled study
performed by the Medical Research Council that dem-
onstrated that folic acid could prevent NTDs. (35) Based
on this and other publications, the United States Food
and Drug Administration (FDA) recommended that fo-
lic acid be added to grains, and the grain industry com-
plied. Although only 50% of the amount recommended
by the Institute of Medicine was added to the grain
supply, the incidence of NTDs was reduced. Proponents
of doubling the amount of folic acid in the grains claimed
that all the preventable NTDs were not being prevented.
(15)(36)(37)(38)(39)(40) The situation is worse in the
rest of the world because only 10% of the world’s popu-
lation is receiving additional folic acid in the grain supply,
which suggests that 90% of the populations in the devel-
oping nations are not receiving adequate amounts of
folic acid. Only a small proportion of women take 400g
of folic acid and 6 to 8 g of vitamin B-12 in a multivi-
tamin each day. Because of inadequate supplementation
of grains, especially corn meal, even in the United States,
a significant proportion of the pop-
ulation is not receiving adequate
folic acid and vitamin B-12 to
prevent all folic acid-preventable
NTDs.
Tens of thousands of children
are born each year with folic acid-
preventable NTDs. The United
States spends $200,000,000 each
year to eradicate poliomyelitis
through an excellent program of
polio immunization, and frequent
epidemiologic monitoring of the
incidence of poliomyelitis provides
data on the changing incidence of
the disease (personal communica-
tion, G.P. Oakley Jr, 2010). The
program has reduced the incidence
of polio to 1,000 cases per year.
Polio may never be eliminated be-
cause of subclinical infections and
the possibility of new mutated
strains, in contrast with smallpox.
The CDC has been provided with a
budget of $5,000,000 for the pre-
vention of the approximate 200,000
folic acid-preventable NTDs worldwide. Thus, the United
States is spending $200,000 for each case of polio pre-
vented and $25 for each NTD case prevented.
Iodine Deficiencies
Iodine deficiency as a cause of intellectual disability and
goiter was recognized by a Swiss physician almost 200
years ago, (41) but the Swiss Academy rejected the
findings. One hundred years elapsed before iodine defi-
ciency as a clinical entity was supported by other scien-
tists. (41) In many parts of the world, the soil is deficient
in iodine, and goiters, hypothyroidism, and cretinism
have been endemic. (42)(43) In 2007, theWorld Health
Organization estimated that 2 billion individuals had
insufficient iodine intake. Iodine deficiency is considered
the single greatest preventable cause of intellectual dis-
ability. These problems were reduced or eliminated in
the United States with the addition of sodium iodide to
salt, referred to as “iodized salt.” However, iodide defi-
ciency may return to the United States with the emphasis
on reducing salt intake to reduce the incidence of hyper-
tension, especially if restaurants and prepared food prod-
uct manufacturers also reduce the amount of salt in their
products. The FDA and some pharmaceutical companies
are considering the addition of potassium iodide or so-
Table 3. Advances in Teratology, Molecular
Biology, Epidemiology, Clinical Teratology,
and Genetics
• Correct number of chromosomes: 46 (1)
• Karyotyping and the discovery of chromosomal diseases
• Advances in molecular biology
• Development of the principles of teratology
• Improvement in the techniques of counseling parents about causes and risks
• Increasing number of identified genetic diseases that are responsible for
congenital malformations and developmental problems
• Continuing discovery of new teratogens (3 in 1950 to more than 52 in 2008)
• Invention and application of computed tomography scans, magnetic resonance
imaging, and diagnostic ultrasonography
• Development and implementation of the administration of rubella vaccination
• Folic acid supplementation to wheat grains and the prevention of folic acid-
preventable neural tube defects
• Creation of the Online Mendelian Inheritance in Man program on the internet
for diagnosing genetic diseases (10)(11)
• Introduction of fetal therapy and accompanying controversies
• Improvement in the control and management of diabetes during pregnancy
• The Human Genome Project (12)
• Determination of the vulnerability of the embryo at different stages of
development
• Fetal therapy and intervention based on the wishes of the parents after
thorough discussion of the risks and benefits
genetics preventing congenital malformations
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Table 4. Environmental Agents or Milieus That May Increase the Risk or
Be Associated With an Increased Risk of Reproductive or
Developmental Effects
Agents
• Alcohol (ethyl alcohol)
• Aminopterin, methotrexate
• Androgens
• Angiotensin-converting enzyme inhibitors
• Angiotensin II receptor blocker (sartans)
• Antidepressants (selective serotonin reuptake inhibitors)
• Antituberculosis therapy
• Caffeine
• Carbamazepine
• Cocaine
• Cobalt used in hematinic vitamin preparation
• Coumarin derivatives
• Cyclophosphamide
• Diethylstilbestrol
• Diphenylhydantoin
• Lithium carbonate (salts)
• Methimazole
• Minoxidil
• Misoprostol
• Mycophenolate mofetil
• Penicillamine (D-penicillamine)
• Phenobarbital
• Progestational drugs
• Retinoids administered systemically (isotretinoin,
etretinate)
• Retinoids administered topically
• Streptomycin
• Tetracyclines
• Thalidomide
• Trimethoprim
• Valproic acid
• Vitamin D
Procedures
• Chorionic villous sampling
• Insulin shock therapy
• Methylene blue intrauterine instillation
• Radiation: radioactive isotopes (radionuclides)
• Radiation: external diagnostic or therapeutic ionizing
radiation
• Ultrasonography
Environmental Exposures
• Carbon monoxide (maternal) poisoning
• Electromagnetic fields
• Environmental chemicals (eg, dioxin, Agent Orange,
phthalates, bisphenol A)
• Lead
• Methyl and ethyl mercury “poisoning”
• Polychlorinated biphenyls
• Smoking tobacco and absorption of nicotine and
other products contained in tobacco
• Toluene and gasoline inhalation addiction
Environmental Conditions
• Diabetes
• Endocrinopathy
• Hyperthermia
• Folic acid and vitamin B-12 (risk of deficiency)
• Iodide deficiency
• Phenylketonuria (maternal)
• Mechanical problems in utero
• Nutritional deprivation
• Obesity
• Thyroid hypofunction (iodine deficiency,
I-131 administration, antithyroid drugs)
• Vitamin A excess and deficiency
Infectious Diseases
• Fetal infections
• Cytomegalovirus
• Herpes simplex 1 and 2
• Human immunodeficiency virus
• Parvovirus B19
• Rubella virus
• Rubella vaccine
• Syphilis
• Toxoplasma
• Varicella-zoster
• Venezuelan equine virus encephalitis
Reproductive or developmental effects include congenital malformations, miscarriage, growth restriction, and neurobehavioral effects. Published articles
addressing these reproductive or developmental agents can be found on the TERIS web site, (17) which provides the risk estimate for each agent and the
quality of the available literature. Other drugs, chemicals, and environmental situations (eg, obesity) that may affect the embryo/fetus can be obtained from
the TERIS web site and Shepard (now on the TERIS web site).
genetics preventing congenital malformations
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dium iodide to multivitamin preparations. Young infants
should ingest 40 g/day of iodine, and women require
150 g/day during pregnancy. (44)
Down Syndrome
The incidence of Down syndrome in the United States
has increased significantly since 1980. In 1980, the prev-
alence was 0.99 per 1,000 births, with 3,579 affected
newborns in the United States. In 2003, the prevalence
of Down syndrome was 1.5 per 1,000 births, with 6,134
affected newborns, reflecting a 71% increase in numbers
and 52% increase in prevalence. (45) In 1980, 4.57%
births were in women older than 35 years. In 2003,
14.04% of births occurred in women older than 35 years.
The increase in pregnancies in older women related to
women postponing marriage and pregnancy for educa-
tion or professional reasons make this a difficult problem
to solve.
Clinical Evaluation
The physician responding to the question, “What caused
my child’s birth defect?” should perform the same schol-
arly analysis required for a differ-
ential diagnosis of any compli-
cated clinical problem. If the
mother of a malformed infant had
some type of exposure during
pregnancy, such as a diagnostic
radiologic examination or medi-
cation, the consulting physician
should not support or suggest the
possibility of a causal relationship
before performing a complete
evaluation. Similarly, if a pregnant
woman who has not yet delivered
had some type of exposure during
pregnancy, the consulting physi-
cian should not support or sug-
gest the possibility that the fetus is
at increased risk before perform-
ing a complete evaluation.
Many articles and books can as-
sist the physician with the clinical
evaluation, although general pedi-
atric training programs do not usu-
ally prepare generalists to perform
sophisticated genetic or teratology
counseling. (11)(24)(25)(26)(27)
(28)(29)(30) In addition to per-
forming the usual history and
physical evaluation, the physician must obtain infor-
mation about the nature, magnitude, and timing of
the exposure. The physical examination should in-
clude descriptive and quantitative information about
the physical characteristics of the child. Although
some growth measurements are routine, many mea-
surements used by specialized counselors are not part
of the usual physical examination, such as palpebral
fissure size, ear length, intercanthal distances, total
height-to-trunk ratio, and many other findings. Im-
portant physical variations in facial, hand, and foot
structure as well as other anatomic structures may be
suggestive of known syndromes, either teratologic or
genetic.
Evaluating the Potential Risks of
Environmental Exposure
Most consultations involving pregnancy exposures con-
clude that the exposure does not change the reproduc-
tive risks in that pregnancy. In many instances, the avail-
able information is so vague that the counselor cannot
reach a definitive conclusion about the magnitude of the
Table 5. Prevention of Congenital Malformation
and Perinatal Disease
1. Rubella vaccination
2. Folic acid (400 g/day), vitamin B-12 supplementation (6 g/day)
3. Supplementation of iodine to deficient populations
4. Diagnosis and management of maternal hypothyroidism
5. Meticulous diabetic control and eventually the prevention or cure of diabetes
6. Obesity control (reduces the risk of birth defects and decreases the risk of
developing diabetes)
7. Human immunodeficiency virus screening and treatment
8. Vaccination with group B Streptococcus vaccine
9. Maternal phenylalanine management for phenylketonuria
10. Management or discontinuation of oral anticoagulants, anticonvulsants,
retinoids, thalidomide, and all known teratogens
11. Recognition that that new teratogens can be represented in the next new
drug or chemical: angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, mycophenolate
12. Cessation of maternal smoking and alcohol ingestion
13. Immunization against known teratogenic infections (botulin toxin vaccine for
the pregnant mother to prevent infant botulism)
14. Reducing the incidence of multiple births following in vitro fertilization
15. Counseling older women and men about the increased risk of Down syndrome
and other genetically determined diseases in older couples contemplating
pregnancy
16. Screening for chromosome abnormalities and genetic disease: amniocentesis,
chorionic villous sampling, maternal serum monitoring, and ultrasonographic
monitoring to diagnose identifiable genetic diseases, karyotype abnormalities,
and serious birth defects to inform the parents about their risks and options
genetics preventing congenital malformations
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risk. Information that is necessary for this evaluation
includes:
● What was the nature of the exposure?
● Is the exposure agent identifiable? If the agent is iden-
tifiable, has it been identified definitively as a reproduc-
tive toxin causing a recognized constellation of malfor-
mations or other reproductive effects?
● When did the exposure occur during embryonic and
fetal development?
● If the agent is known to produce reproductive toxic
effects, was the exposure above or below the threshold
for these effects?
● Were there other significant environmental exposures
or medical problems during the pregnancy?
● Is this a wanted pregnancy or is the family ambivalent
about carrying this baby to term?
● What is the medical and reproductive history of the
mother with regard to previous pregnancies and the
reproductive history of the family lineage?
Teratology Principles
A number of important clinical rules are important when
determining the cause of a patient’s congenital malfor-
mations. (6)(7)(9)(14)
● No teratogenic agent should be described qualitatively
as a teratogen because a teratogenic exposure includes
not only the agent, but also the dose and the time in
pregnancy when the exposure has the potential for
causing CMs and other developmental effects.
● Even agents that have been demonstrated to result in
malformations cannot produce every type of malfor-
mation. Known teratogens may be implicated pre-
sumptively by the spectrum of malformations they
produce (the syndrome that describes the clinical man-
ifestations of the teratogenic agent). However, differ-
ent teratogenic agents may affect the fetus with a
similar spectrum of malformations, thus preventing the
physician from providing the family with a definitive
diagnosis. Some teratogenic syndromes mimic genetic
syndromes, such as thalidomide effects mimicking
Holt-Oran syndrome. It is easier to exclude an agent as
a cause of birth defects than to conclude definitively
that it was responsible for birth defects because of the
existence of genocopies of some teratogenic syn-
dromes.
● The dose is a crucial component when evaluating the
risk of exposures. Teratogenic agents follow a toxico-
logic dose-response curve, which means that each tera-
togen has a threshold dose, belowwhich there is no risk
of teratogenesis, no matter when in pregnancy the
exposure occurred.
● The evaluation of a child born with CMs cannot be
performed adequately unless it is approached with the
same scholarship and intensity as the evaluation of any
other complicated medical problem.
● Each physician must recognize the consequences of
providing erroneous information on reproductive
risks to pregnant women exposed to drugs and
chemicals during pregnancy or alleging that a child’s
malformations are due to an environmental agent
without performing a complete and scholarly evalu-
ation.
● Reproductive problems alarm the public, the press,
and some scientists to a greater degree than most
other diseases. In fact, severely malformed children
are disquieting to clinicians, especially those inexpe-
rienced in dealing with these problems. No physician
is comfortable informing a family that their child was
born without arms and legs. The objective evalua-
tion of environmental causes of reproductive dis-
eases is clouded by the emotional climate that sur-
rounds these diseases, resulting in the expression of
partisan positions that either diminish or magnify the
environmental risks. Such nonobjective opinions can
be expressed by scientists, the public, or the press.
(31) Every physician must be aware of the emotion-
ally charged situation when a family has a child born
with a birth defect.
Environmental Exposures Occurring During
Pregnancy
After obtaining all this information, the counselor is in a
position to provide the family with an estimate of the
reproductive risks of the exposure. Following are some
examples of consultations that have been referred to our
clinical teratology service:
Patient 1. A 33-year-old mother of two was diagnosed
with breast cancer, and her only treatment was radiation
therapy to the left breast. She had a very good prognosis
because the disease was only in the breast and there were no
positive axillary lymph nodes. She underwent 6 weeks of
radiation therapy. In the third week of therapy, it was
determined that she was 8 weeks postconception. The oncol-
ogist and radiation therapist suggested that the pregnancy
should be interrupted. The woman continued her radiation
therapy to her breast but refused the interruption of her
pregnancy and requested another opinion. The radiation
therapist informed our office that the mother was receiving
2.25 Gy/day to her left breast. The health physicist calcu-
lated the fetal exposure to be 0.017 Gy for each therapy
genetics preventing congenital malformations
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session, which indicated that the fetus would receive 0.425
Gy (42.5 rads) during 25 radiation sessions over a period of
5 weeks. The mother asked to speak with the physician
directly because she wanted the answers to several questions:
1) “Could the child be malformed?” Answer: The fetus had
a 3% risk of malformation and a 15% of miscarriage
because that is the background risk for all women. The risks
would not be increased by the radiation exposure because of
the protracted exposure over a 5-week period. 2) “Could the
child have growth restriction?” Answer: Approximately 4%
to 10% of children experience growth restriction, and it is
unlikely that the protracted radiation exposure would have
a marked effect on growth, but it is possible. 3) “Could my
child be normal?” There is a greater than 90% chance that
the child will be normal. This mother told her physicians
that she was not interrupting the pregnancy. She delivered
a 6 lb 11oz boy who was physically healthy after a careful
evaluation.
Patient 2. A 34-year-old pregnant laboratory worker
dropped and broke a reaction vessel containing a mixture
of chemical reagents. After cleaning the floor with paper
towels, she became concerned about the potential harmful
effects of the exposure. She was in the sixth week of her
pregnancy, which means that the embryo was in the period
of organogenesis. The chemicals in the spill were tetrahydro-
furan (70%,) pyridine (20%), and iodine (1%). It was not
possible to estimate the quantitative exposure to the agents,
but the laboratory worker experienced no symptoms from the
exposure. The pregnancy was planned and wanted. Al-
though iodine can interfere with thyroid development, the
exposure in this situation would be inconsequential because
the thyroid gland is not yet present in the fetus. The other
two compounds have not been evaluated in epidemiologic
studies of pregnant women. No other exposure to reproduc-
tive toxins occurred in this pregnancy, and the family
history for CMs was negative. The woman was advised that
this exposure was very unlikely to increase her teratogenic
risk because the exposures to the embryo would be extremely
low. She was also told that she still faced the background
risks for birth defects andmiscarriage. Therefore, her repro-
ductive risks should be the same as the risks for the general
population. The infant was healthy at birth and weighed
3,170 g.
Patient 3. A 26-year-old woman was in an automo-
bile crash in her tenth week of pregnancy and sustained a
severe concussion. Although she did not convulse postin-
jury, the treating neurosurgeon prescribed 300 mg of
diphenylhydantoin during her first 24 hours in the hos-
pital. She recovered from the injury without any se-
quelae, but her primary physician was concerned that she
had received an anticonvulsant associated with a tera-
togenic syndrome. No other exposure to reproductive
toxins occurred in this pregnancy, and the family history
for CMs was negative, except for an uncle who was born
with neurofibromatosis. The primary physician requested
a consultation about the teratogenic risk. Although di-
phenylhydantoin administered chronically throughout
pregnancy has been associated with a low incidence of
characteristic facial dysmorphogenesis, reduced menta-
tion, cleft palate, and digital hypoplasia, no data indi-
cate that 1 day of therapy would cause any of the features
of this syndrome. Furthermore, the lip and palate have
completed their development by the 10th week of gesta-
tion. The mother chose to continue her wanted pregnancy
and delivered a healthy 3,370-g boy at term.
Patient 4. A 25-year-old woman was seen in the emer-
gency service of her local hospital because of nausea, vomit-
ing, and diarrhea. She had just returned from a cruise on
which a number of the passengers became ill with similar
symptoms. The emergency department physician ordered a
pregnancy test followed by a radiograph of the abdomen
because there was evidence of peritoneal irritation. Results
of both studies were negative. However, 1 week later, the
womanmissed her menstrual period, and 2 weeks later, her
pregnancy test was positive. Her obstetrician was concerned
because she had been exposed to a radiologic procedure at a
time when she was pregnant and referred her for counseling
after obtaining ultrasonography that indicated that the
embryo was approximately 7 days postconception at the time
of the radiologic examination. The patient advised the
counselor that she was ambivalent about the pregnancy
because of the “dangers” of the radiographs to her embryo.
The estimated exposure to the embryo was less than 500
mrad (0.005 Sv), which is far below the exposure known to
affect the developing embryo. Further, the embryo was ex-
posed during the first 2 weeks postconception (all or none
period), a time that is less likely to increase the risk of
teratogenesis, even if the exposure had been much higher.
After evaluation of the family history and after she received
counseling about the risks of the radiograph, the prospective
mother decided to continue the pregnancy. She delivered a
3,150-g healthy baby.
Evaluating the Cause of a Congenital
Malformation
Patient 5. A mother of a 30-year-old man born in the
Azores in 1960 who had congenital absence of the right
leg below the knee had pursued compensation for her son
because she was certain that she must have received
thalidomide during her pregnancy. The German man-
ufacturer of thalidomide refused compensation, claim-
ing that thalidomide had never been distributed in the
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Azores. The mother fervently believed that thalidomide
was responsible for her son’s malformations and asked for
a further opinion. Review of the radiographs of his hips
and legs and reports of his complete evaluation per-
formed at the local hospital in the Azores revealed no
other stigmata of thalidomide embryopathy (preaxial
limb defects, phocomelia, facial hemangioma, ear mal-
formations, deafness, crocodile tears, ventricular septal
defect, intestinal or gall bladder atresia, kidney malfor-
mations). Most importantly, his limb malformations
were not of the thalidomide type. He had a unilateral
congenital amputation, with no digital remnants at the
end of the limb. His pelvis girdle was completely normal,
which would be unusual in a thalidomide-malformed
limb. Finally, his limb defect involved only one leg; the
other leg was completely normal, a finding that is very
unusual in a true thalidomide embryopathy. The young
man had a congenital amputation, probably due to
vascular disruption, cause unknown. Known causes of
vascular disruptive malformations are placental emboli,
cocaine or misoprostol exposure, and chorionic villous
sampling.
Patient 6. A family claimed that the antinausea med-
ication bendectin, taken by the mother of a malformed boy,
was responsible for her son’s congenital limb reduction
defects. The mother took the medication after the period of
limb organogenesis, but some limb malformations can be
produced by environmental insults later in pregnancy. The
malformation was unaccompanied by any other dysmor-
phogenetic effects. The boy’s malformation was the classic
split-hand, split-foot syndrome, which is inherited domi-
nantly. In a significant portion of cases, this malformation
is due to a new mutation. Because neither parent mani-
fested the malformation, the logical conclusion was that
a new mutation had occurred in the sex cell of one of the
parents. Therefore, the risk of this malformation occur-
ring in the offspring of this boy would be 50%. Bendectin
obviously was not responsible for this child’s malforma-
tions. In spite of the obvious genetic cause of the mal-
formed child’s birth defects, a legal suit was filed, and a
jury decided that bendectin was not responsible for the
child’s birth defects.
Patient 7. A woman visited the emergency depart-
ment of a university hospital complaining of severe lower
abdominal pain. An obstetric resident saw her because
she informed the staff that she had experienced a previous
ectopic pregnancy that necessitated the removal of one
ovary and tube. A pregnancy test was positive, and she
was scheduled to return to the obstetric clinic in 1 week.
At that time, her chorionic gonadotropin assessment was
repeated and had not changed from its previous value.
Without performing ultrasonography, ectopic pregnancy
was diagnosed. To preserve the patient’s reproductive
potential, it was decided to treat the ectopic pregnancy
with methotrexate rather than remove the remaining
tube and ovary. Following the administration of metho-
trexate, the patient was sent home, but a laboratory
report subsequently was received that indicated that the
gonadotropin value had increased fivefold; the labora-
tory report received earlier in the day was a copy of the
original report performed a week earlier. The patient
was called back to the hospital, and ultrasonography
revealed a normally implanted embryo. The senior ob-
stetric staff counseled the mother that the baby was at
increased risk for CMs because of the exposure. The
patient refused to abort the pregnancy. The obstetric
department offered to provide care for the pregnancy
and delivery that included serial ultrasonography. At
28 weeks’ gestation, the patient went into labor and
delivered a liveborn preterm infant. During infancy,
hydrocephalus, developmental delay, and spastic cerebral
palsy were diagnosed. The family filed a lawsuit against
the doctors and the university hospital. The attorney
representing the child requested an evaluation of the
allegation that the child’s abnormalities were due to the
administration of the methotrexate. Methotrexate has
been reported to cause growth restriction, microcephaly,
developmental delay, and hydrocephalus but not prema-
turity. Review of the records revealed that ultrasonogra-
phy performed 1 week before the preterm delivery showed
no evidence of hydrocephalus and that the birthweight
was appropriate for the gestational stage. The exposure to
methotrexate was not responsible for the serious problems
in this infant; the hydrocephalus and neurologic symp-
toms were due to an intracranial hemorrhage in the
postnatal period as a complication of the prematurity.
As these case reports indicate, determining the repro-
ductive risks of an exposure during pregnancy or the
cause of a child’s CM is not a simple process. It involves
a careful analysis of the medical and scientific literature
pertaining to the reproductive toxic effects of exogenous
agents in humans and animals as well as an evaluation of
the exposure and biologic plausibility of an increased risk
or a causal connection between the exposure and a
child’s CM. Evaluation must include a careful physical
examination in addition to a review of the scientific
literature pertaining to genetic and environmental causes
of the malformations in question. Abridged counseling,
based on superficial and incomplete analyses, is a disser-
vice to the family.
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PIR Quiz
Quiz also available online at http://pedsinreview.aappublications.org.
NOTE: Beginning in January 2012, learners will only be able to take Pediatrics in Review quizzes and claim credit
online. No paper answer form will be printed in the journal.
1. One of the principal advances in teratology over the past five decades is the discovery that:
A. Exposure to teratogenic agents late in the second trimester may mar fetal development.
B. Most congenital malformations can be explained by exposure to teratogens.
C. Teratogenic syndromes cannot be confused with genetic mimics.
D. The effects of exposure to a teratogenic are independent of timing.
E. The effects of teratogenic agents are independent of dose.
2. Which of the following is a drug that has established teratogenic potential?
A. Amlodipine.
B. Clonidine.
C. Hydrochlorothiazide.
D. Misoprostrol.
E. Metoproterenol.
3. Neural tube defects can be prevented best by assuring adequate folic acid and vitamin B-12 intake:
A. Before pregnancy.
B. In pregnant women who have a family history of neural tube defects.
C. No later than the beginning of the second trimester.
D. Throughout the third trimester.
E. Upon diagnosis of pregnancy.
4. A fetus was exposed to radiation via radiotherapy of the mother’s breast cancer over a 5-week period
beginning at the 8th week of gestation. The infant at term is most likely to be:
A. Deformed.
B. Large for age but otherwise normal.
C. Malformed.
D. Normal in all respects.
E. Small for age but otherwise normal.
5. An embryo was exposed at 7 days of gestation to radiation when the mother received a single abdominal
flat plate radiographic study to evaluate severe abdominal tenderness. The infant at term is most likely to
be:
A. Deformed.
B. Large for age but otherwise normal.
C. Malformed.
D. Normal in all respects.
E. Small for age but otherwise normal.
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Things You Need To Know About Birth Defects
4. Did you know that some birth defects can be 
diagnosed before birth?
Fact:  Tests like an ultrasound and amniocentesis can 
detect birth defects such as spina biﬁda, heart defects, 
or Down syndrome before a baby is born. Prenatal 
care and screening are important because early 
diagnosis allows families to make decisions and plan 
for the future.
5. Did you know that birth defects can greatly aﬀect  
the ﬁnances not only of the families involved,  
but of everyone?
Fact:   In the United States, birth defects have 
accounted for over 139,000 hospital stays during a 
single year, resulting in $2.5 billion in hospital costs 
alone. Families and the government share the burden 
of these costs. Additional costs due to lost wages or 
occupational limitations can aﬀect families as well.
1. Did you know that birth defects are common?
Fact:  Birth defects aﬀect 1 in 33 babies every year 
and cause 1 in 5 infant deaths. For many babies 
born with a birth defect, there is no family history 
of the condition.
2. Did you know that a woman should take folic acid 
during her teens and throughout her life?
Fact:  Because half of all pregnancies in the United 
States are not planned, all women who can become 
pregnant should take a vitamin with folic acid every 
day. Folic acid helps a baby’s brain and spine develop 
very early in the ﬁrst month of pregnancy when a 
woman might not know she is pregnant.
3. Did you know that many birth defects are 
diagnosed after a baby leaves the hospital?
Fact: Many birth defects are not found 
immediately at birth. A birth defect can aﬀect 
how the body looks, how it works, or both. Some 
birth defects like cleft lip or spina biﬁda are easy 
to see. Others, like heart defects, are not.
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6. Did you know that birth defects can be caused 
by many diﬀerent things, not just genetics?
Fact:  The cause of most birth defects is unknown. Use 
of cigarettes, alcohol, and other drugs, taking of some 
medicines; and exposure to chemicals and infectious 
diseases during pregnancy have been linked to birth 
defects. Researchers are studying the role of these 
factors, as well as genetics, as causes of birth defects.
7. Did you know that some birth defects can 
be prevented?
Fact:  A woman can take some important steps 
before and during pregnancy to help prevent birth 
defects. She can take folic acid; have regular medical 
checkups; make sure medical conditions, such as 
diabetes, are under control; have tests for infectious 
diseases and get necessary vaccinations; and not use 
cigarettes, alcohol, or other drugs.
8. Did you know there are ways a pregnant woman 
can keep her unborn baby safe from infections?
Fact:  The best way to keep an unborn baby safe from 
infections is for a pregnant woman to wash her hands 
often, especially after using the bathroom; touching 
raw meat, uncooked eggs, or unwashed vegetables; 
handling pets; gardening; or caring for small children.
To ﬁnd out more about birth defects and healthy pregnancies, please visit the 
Centers for Disease Control and Prevention website 
www.cdc. gov/pregnancy or call your state or local health department.
This fact sheet was developed in partnership with the National Birth Defects Prevention Network (NBDPN).
9. Did you know there is no known safe amount of 
alcohol or safe time to drink during pregnancy?
Fact:  Fetal alcohol spectrum disorders (FASDs) are a 
group of conditions that can occur in a person whose 
mother drank alcohol during pregnancy. These ef-
fects can include physical problems and problems 
with behavior and learning which can last a lifetime. 
There is no known safe amount, no safe time, and 
no safe type of alcohol to drink during pregnancy. 
FASDs are 100% preventable if a woman does not 
drink alcohol while pregnant.
10. Did you know that an unborn child is not always 
protected from the outside world?
Fact:  The placenta, which attaches 
a baby to the mother, is not a strong 
barrier. When a mother uses cigarettes, 
alcohol, or other drugs, or is exposed 
to infectious diseases, her baby is 
exposed also. Healthy habits like 
taking folic acid daily and eating 
nutritious foods can help ensure 
that a child is born healthy.
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